Nextplat Corp 10-K Summary: Fiscal Year Ended December 31, 2025
Business Context and Reporting Period
Company: Nextplat Corp (NXPL)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Model: Nextplat operates two primary segments: e-Commerce Operations (satellite communications products and services) and Healthcare Operations (pharmacy services, 340B contract pharmacy, and data analytics). The company serves global markets through proprietary websites, third-party marketplaces (notably Amazon), and physical pharmacy locations primarily in Florida.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Net Revenue | $54,322 | $66,082 |
| Gross Profit | $10,906 | $17,008 |
| Gross Margin | 20.1% | 25.7% |
| Operating Expenses | $19,906 | $40,033 |
| Net Loss | $(10,463) | $(22,526) |
| Cash and Equivalents (Year End) | $13,709 | $19,960 |
| Working Capital | $15,030 | $23,869 |
| Total Debt (Notes Payable) | $1,292 | $1,412 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 18% ($11.8 million) year-over-year. This was driven by a significant 61% drop in Pharmacy 340B contract revenue ($6.4 million decrease) and a 15% decline in standard pharmacy prescription revenue. These declines were partially offset by a 6% increase in e-Commerce revenue.
- Margin Compression: Gross margin fell from 26% to 20%. The Healthcare segment margin dropped to 19% due to lower 340B volumes. The e-Commerce margin decreased to 23% following the expiration of a favorable airtime service contract in late 2024.
- Expense Reduction: Operating expenses decreased 50% ($20.1 million). This improvement was primarily due to the absence of a $13.7 million non-recurring impairment loss recorded in 2024 (related to goodwill and intangible assets). Additionally, salaries and professional fees were reduced through headcount reductions and lower legal/consulting costs.
- Net Loss Improvement: Net loss improved by 54% to $10.5 million, largely attributable to the elimination of the prior year's impairment charges and reduced operating expenses.
Guidance, Outlook, Risks, and Unusual Items
- Listing Status Risk: The company received notice from Nasdaq regarding failure to meet the $1.00 minimum bid price requirement. Shareholders approved a 1-for-10 reverse stock split on March 27, 2026, to regain compliance. Failure to maintain the price above $1.00 post-split could result in delisting.
- Legal Contingencies:
- Merger Litigation: A putative class action suit regarding the 2024 RXMD merger remains pending. The company accrued $1.75 million for this liability, classified as a contingent loss in "Other expense."
- Employment Arbitration: Settled for $250,000 (cash and stock) in November 2025.
- Internal Control Weaknesses: Management identified material weaknesses in internal controls regarding the accounting for PBM performance bonus receivables and the valuation of modified PIPE warrants. Remediation plans are underway.
- Supplier Concentration: The Healthcare segment relies heavily on a single supplier, McKesson, for approximately 98% of pharmaceutical purchases. The e-Commerce segment derives 31% of its revenue from Amazon.
- Outlook: Management believes current cash resources ($13.7 million) are sufficient to fund operations for the next 12 months. Strategy focuses on cost reduction, expanding government sales (GSA), and selective acquisitions.
Investor Verification Checklist
- Reverse Stock Split Effectiveness: Verify if the stock price has stabilized above $1.00 following the March 2026 split to avoid Nasdaq delisting.
- 340B Revenue Sustainability: Assess the long-term viability of the 340B contract pharmacy model given the 61% revenue drop and regulatory scrutiny mentioned in the filing.
- Internal Control Remediation: Monitor progress on fixing material weaknesses related to accounting estimates and warrant valuations to ensure future financial statement reliability.
- Litigation Exposure: Track the status of the RXMD merger class action to determine if the $1.75 million accrual is sufficient or if further losses are probable.
- Supplier Dependency: Evaluate the risk of supply chain disruption given the 98% reliance on McKesson for pharmaceuticals and 31% revenue reliance on Amazon.